Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Diabetologia ; 55(7): 1926-36, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22441569

ABSTRACT

AIMS/HYPOTHESIS: The aim of the study was to investigate the timing of the appearance of autoantibodies associated with type 1 diabetes between birth and puberty, the natural fate of these autoantibodies and the predictive power of autoantibody concentrations for early progression to clinical diabetes. METHODS: Children were recruited to the Type 1 Diabetes Prediction and Prevention Project, an ongoing study based on HLA-conferred genetic risk. Autoantibodies against islet cells, insulin, GAD65 and islet antigen 2 were analysed at 3-12 month intervals, starting from birth. RESULTS: During the follow-up, 1,320 children (18.4% of the cohort of 7,165 children) were autoantibody positive in at least one sample. Altogether, 184 autoantibody-positive children progressed to type 1 diabetes. Seroconversion occurred at an early age in the progressors (median 1.5 years), among whom 118 (64%) and 150 (82%) seroconverted to autoantibody positivity before the age of 2 and 3 years, respectively. The incidence of seroconversion peaked at 1 year of age. Compared with other autoantibody-positive children, the median autoantibody levels were already markedly higher 3 to 6 months after the seroconversion in children who later progressed to diabetes. CONCLUSIONS/INTERPRETATION: Early initiation of autoimmunity and rapid increases in autoantibody titres strongly predict progression to overt diabetes before puberty, emphasising the importance of early life events in the development of type 1 diabetes.


Subject(s)
Autoantibodies/blood , Diabetes Mellitus, Type 1/immunology , HLA Antigens/immunology , Prediabetic State/immunology , Age of Onset , Autoantibodies/genetics , Autoantibodies/immunology , Biomarkers/blood , Child, Preschool , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 1/epidemiology , Diabetes Mellitus, Type 1/genetics , Disease Progression , Disease Susceptibility , Female , Finland/epidemiology , HLA Antigens/genetics , Humans , Infant , Infant, Newborn , Male , Predictive Value of Tests , Pregnancy
2.
Endocrinology ; 142(12): 5371-8, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11713237

ABSTRACT

Decreased E2 levels after menopause cause bone loss through increased penetrative resorption. The reversal effect of E2 substitution therapy is well documented in vivo, although the detailed mechanism of action is not fully understood. To study the effects of E2 on bone resorption, we developed a novel in vitro bone resorption assay in which degradation of inorganic and organic matrix could be measured separately. E2 treatment significantly decreased the depth of resorption pits, although the area resorbed was not changed. Electron microscopy further revealed that the resorption pits were filled with nondegraded collagen, suggesting that E2 disturbed the organic matrix degradation. Two major groups of proteinases, matrix metalloproteinases (MMPs) and cysteine proteinases, have been suggested to participate in organic matrix degradation by osteoclasts. We show here that MMP-9 released a cross-linked carboxyl-terminal telopeptide of type I collagen from bone collagen, and cathepsin K released another C-terminal fragment, the C-terminal cross-linked peptide of type I collagen. E2 significantly inhibited the release of the C-terminal cross-linked peptide of type I collagen into the culture medium without affecting the release of cross-linked carboxyl-terminal telopeptide of type I collagen in osteoclast cultures. These results suggest that organic matrix degradation is initiated by MMPs and continued by cysteine proteases; the latter event is regulated by E2.


Subject(s)
Bone Matrix/metabolism , Bone Resorption/pathology , Estradiol/pharmacology , Osteoclasts/drug effects , Osteoclasts/physiology , Animals , Biomarkers , Bone and Bones/metabolism , Cathepsin K , Cathepsins/pharmacology , Cell Count , Cells, Cultured , Cellular Senescence/physiology , Collagen/metabolism , In Vitro Techniques , Matrix Metalloproteinase 9/metabolism , Matrix Metalloproteinase 9/pharmacology , Microscopy, Electron, Scanning , Osteoclasts/ultrastructure , Protease Inhibitors/pharmacology , Rats , Recombinant Proteins
3.
Biochem Biophys Res Commun ; 288(1): 142-50, 2001 Oct 19.
Article in English | MEDLINE | ID: mdl-11594765

ABSTRACT

Tartrate-resistant acid phosphatase (TRAP) is an enzyme expressed specifically in osteoclasts and activated macrophages, two phagocytosing cell types originating from the same hematopoietic stem cells. TRAP contains a binuclear iron centre which has been shown to generate reactive oxygen species (ROS). In this study murine macrophage like cell line RAW-264 overexpressing TRAP was shown to produce elevated levels of hydroxyl radicals compared to parental cells. TRAP transfected cells also had reduced growth rate indicating harmful effects of excessive intracellular ROS levels. Using TRAP specific antibody TRAP protein was shown in alveolar macrophages partially colocalize with late endosomal/lysosomal markers Rab7, Lamp 1 and MHC II molecules that bind antigenic peptides. TRAP also colocalized into compartments where Staphylococcus aureus were phagocytosed. These results suggest that TRAP may have an important biological function in the defence mechanism of macrophages by generating intracellular ROS which would be targeted to destroy phagocytosed foreign material.


Subject(s)
Acid Phosphatase/physiology , Hydroxyl Radical/metabolism , Isoenzymes/physiology , Macrophages, Alveolar/enzymology , Macrophages, Alveolar/microbiology , Phagocytosis , Acid Phosphatase/genetics , Acid Phosphatase/immunology , Animals , Antibodies/immunology , Cell Division , Cell Line , Cells, Cultured , Humans , Isoenzymes/genetics , Isoenzymes/immunology , Kinetics , Macrophages, Alveolar/cytology , Mice , Phagosomes/chemistry , RNA, Messenger/biosynthesis , Staphylococcus aureus , Tartrate-Resistant Acid Phosphatase , Transfection
4.
J Biol Chem ; 276(42): 39295-302, 2001 Oct 19.
Article in English | MEDLINE | ID: mdl-11514537

ABSTRACT

During skeletal growth and remodeling the mineralized bone matrix is resorbed by osteoclasts through the constant secretion of protons and proteases to the bone surface. This relies on the formation of specialized plasma membrane domains, the sealing zone and the ruffled border, and vectorial transportation of intracellular vesicles in bone-resorbing osteoclasts. Here we show that Rab7, a small GTPase that is associated with late endosomes, is highly expressed and is predominantly localized at the ruffled border in bone-resorbing osteoclasts. The decreased expression of Rab7 in cultured osteoclasts by antisense oligodeoxynucleotides disrupted the polarization of the osteoclasts and the targeting of vesicles to the ruffled border. These impairments caused a significant inhibition of bone resorption in vitro. The results indicate that the late endocytotic pathway is involved in the osteoclast polarization and bone resorption and underscore the importance of Rab7 in osteoclast function.


Subject(s)
Bone Resorption , Down-Regulation , Osteoclasts/metabolism , rab GTP-Binding Proteins/metabolism , Actins/metabolism , Animals , Animals, Newborn , Blotting, Western , Cattle , Cells, Cultured , Dose-Response Relationship, Drug , Extracellular Matrix/metabolism , Microscopy, Confocal , Microscopy, Electron , Microscopy, Fluorescence , Molecular Sequence Data , Oligonucleotides/metabolism , Oligonucleotides, Antisense/metabolism , Protein Binding , RNA, Messenger/metabolism , Rats , Time Factors , Transferrin/metabolism , Transferrin/pharmacokinetics , rab7 GTP-Binding Proteins
SELECTION OF CITATIONS
SEARCH DETAIL
...